[go: up one dir, main page]

MA32686B1 - Composés, compositions et procédés pour le traitement de maladies de la b-amyloïde et de synucléinopathies - Google Patents

Composés, compositions et procédés pour le traitement de maladies de la b-amyloïde et de synucléinopathies

Info

Publication number
MA32686B1
MA32686B1 MA33735A MA33735A MA32686B1 MA 32686 B1 MA32686 B1 MA 32686B1 MA 33735 A MA33735 A MA 33735A MA 33735 A MA33735 A MA 33735A MA 32686 B1 MA32686 B1 MA 32686B1
Authority
MA
Morocco
Prior art keywords
treatment
amyloid
diseases
compounds
sinoclinopathy
Prior art date
Application number
MA33735A
Other languages
Arabic (ar)
English (en)
Inventor
Luke A Esposito
F Michael Hudson
Thomas Lake
Joel Cummings
Manfred Weigele
Alan D Snow
Lesley Larsen
Original Assignee
Proteotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteotech Inc filed Critical Proteotech Inc
Publication of MA32686B1 publication Critical patent/MA32686B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/11—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms
    • C07C37/16—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms by condensation involving hydroxy groups of phenols or alcohols or the ether or mineral ester group derived therefrom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
    • C07C39/10—Polyhydroxy benzenes; Alkylated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/17—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings containing other rings in addition to the six-membered aromatic rings, e.g. cyclohexylphenol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION PORTE SUR DES COMPOSÉS DE DIHYDROXYARYLE ET SUR DES ESTERS PHARMACEUTIQUEMENT ACCEPTABLES, SUR LEUR SYNTHÈSE, SUR DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, ET SUR LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES DE LA ?-AMYLOÏDE, TELLE QUE L'ON PEUT EN OBSERVER DANS LA MALADIE D'ALZHEIMER, ET DE SYNUCLÉINOPATHIES, TELLE QUE L'ON PEUT EN OBSERVER DANS LA MALADIE DE PARKINSON, ET SUR LA FABRICATION DE MÉDICAMENTS POUR UN TEL TRAITEMENT.
MA33735A 2008-10-03 2011-04-01 Composés, compositions et procédés pour le traitement de maladies de la b-amyloïde et de synucléinopathies MA32686B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/244,968 US8829198B2 (en) 2007-10-31 2008-10-03 Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
PCT/US2009/048855 WO2010039308A1 (fr) 2008-10-03 2009-06-26 Composés, compositions et procédés pour le traitement de maladies de la β-amyloïde et de synucléinopathies

Publications (1)

Publication Number Publication Date
MA32686B1 true MA32686B1 (fr) 2011-10-02

Family

ID=40583657

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33735A MA32686B1 (fr) 2008-10-03 2011-04-01 Composés, compositions et procédés pour le traitement de maladies de la b-amyloïde et de synucléinopathies

Country Status (29)

Country Link
US (2) US8829198B2 (fr)
EP (1) EP2328417B1 (fr)
JP (1) JP5431485B2 (fr)
KR (1) KR20110086549A (fr)
CN (1) CN102170787B (fr)
AU (2) AU2009300298A1 (fr)
BR (1) BRPI0920687A2 (fr)
CA (1) CA2735120C (fr)
CL (1) CL2011000739A1 (fr)
CO (1) CO6382089A2 (fr)
CY (1) CY1115725T1 (fr)
DK (1) DK2328417T3 (fr)
ES (1) ES2519140T3 (fr)
HR (1) HRP20140967T1 (fr)
IL (1) IL211313A (fr)
MA (1) MA32686B1 (fr)
ME (1) ME02017B (fr)
MX (1) MX2011002830A (fr)
MY (1) MY156302A (fr)
NZ (1) NZ591504A (fr)
PE (1) PE20110930A1 (fr)
PL (1) PL2328417T3 (fr)
PT (1) PT2328417E (fr)
RS (1) RS53613B1 (fr)
RU (1) RU2501792C2 (fr)
SI (1) SI2328417T1 (fr)
UA (1) UA101393C2 (fr)
WO (1) WO2010039308A1 (fr)
ZA (1) ZA201101278B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090227647A1 (en) * 2008-03-05 2009-09-10 Thomas Lake Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
KR101787112B1 (ko) 2008-06-09 2017-11-15 루드비히-막시밀리안스-우니버지테트 뮌헨 신경변성 질환 및/또는 단백질 응집과 연관된 질환과 관련된 단백질의 응집을 억제하기 위한 신규 약물
WO2011072243A1 (fr) 2009-12-10 2011-06-16 The Trustees Of Columbia University In The City Of New York Activateurs d'histone acétyltransférase et utilisation de ceux-ci
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
US20120251448A1 (en) * 2011-03-03 2012-10-04 Hefti Franz F Compounds for Use in the Detection of Neurodegenerative Diseases
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
RU2614697C1 (ru) * 2016-04-12 2017-03-28 Общество с ограниченной ответственностью "Нормофарм" Нейропротекторное средство
US10889635B2 (en) 2016-11-15 2021-01-12 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
BR112018016717A2 (pt) 2016-12-16 2018-12-26 H Lundbeck As agentes, usos e métodos
EP3920921A4 (fr) * 2019-02-07 2022-11-02 Alsatech, Inc. Dérivés polyvalents d'émoxypine
CN114728927B (zh) * 2019-11-19 2025-08-29 莫达戈有限公司 用于诊断、治疗和预防与α-突触核蛋白的聚集相关的疾病的化合物
CN114573570B (zh) * 2022-02-21 2023-05-30 中山大学 一类α-突触核蛋白靶向化合物及其制备方法和应用
CN115650957B (zh) * 2022-09-16 2023-12-15 中山大学 一类靶向α-突触核蛋白的蛋白水解嵌合体及其应用
WO2025053670A1 (fr) * 2023-09-08 2025-03-13 주식회사 테라노큐어 Composé dérivé d'acide vanillique, composition d'agent thérapeutique pour la maladie d'alzheimer le comprenant, et composition d'agent thérapeutique pour la neuro-inflammation

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4710384A (en) 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5387681A (en) 1992-08-19 1995-02-07 Eli Lilly And Company Synthesis of bicyclic aromatic sulfonic acids sulfonyl chlorides and sulfonamides
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
JP3682075B2 (ja) * 1993-04-16 2005-08-10 クミアイ化学工業株式会社 トリアゾール誘導体及び殺虫、殺ダニ剤
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
TW533205B (en) 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
CA2266629C (fr) 1996-10-01 2002-04-16 Cima Labs Inc. Compositions en microcapsule a masquage de gout et procedes de fabrication
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
JP2004067510A (ja) * 1997-12-26 2004-03-04 Mitsubishi Pharma Corp 新規イミダゾール誘導体
US6288061B1 (en) 1997-12-26 2001-09-11 Welfide Corporation Imidazole derivatives
IT1300055B1 (it) 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
WO2003053986A1 (fr) 2001-12-21 2003-07-03 Ciba Specialty Chemicals Holding Inc. Utilisation de composes de complexes metalliques en tant que catalyseurs d'oxydation
EP2527315B1 (fr) * 2002-05-31 2014-03-19 Proteotech Inc. Composés, compositions et procédés pour le traitement de maladies amyloïdes et de synucléinopathies, comme la maladie d'Alzheimer, le diabète de type 2 et la maladie de Parkinson
US20070276034A1 (en) 2002-05-31 2007-11-29 Luke Esposito Compounds, compositions and methods for the treatment of synucleinopathies
AU2003271117A1 (en) * 2002-10-09 2004-05-04 Ssp Co., Ltd. Novel pyrazole compounds having antifungal activity
EP1603548A4 (fr) 2003-02-05 2007-10-10 Myriad Genetics Inc Composition et methode de traitement de troubles neurodegeneratifs
US20090227647A1 (en) 2008-03-05 2009-09-10 Thomas Lake Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
US8916598B2 (en) * 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
WO2005006945A2 (fr) 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Procedes de traitement de troubles neurologiques et composes utiles a cet effet
JP2007528405A (ja) 2004-03-11 2007-10-11 イーラン ファーマスーティカルズ、インコーポレイテッド Ｎ−置換ベンゼンスルホンアミド
CA2597332A1 (fr) 2005-02-10 2006-08-17 Novartis Ag Procedes d'amelioration du sort de medicaments
JP2008545624A (ja) 2005-05-13 2008-12-18 チバ ホールディング インコーポレーテッド 金属錯体を含むケラチン繊維を着色するための方法
PL1945272T3 (pl) 2005-11-01 2014-03-31 Novartis Ag Sposób prowadzenia scyntygraffi
MX2009001290A (es) 2006-08-04 2009-02-11 Novartis Ag Tratamiento de disfusion endocrina utilizando quelantes de hierro.
EP2144602A1 (fr) 2007-05-14 2010-01-20 Novartis Ag Utilisation d'un chélateur du fer pour le traitement de l'infarctus du myocarde
EP1994930A1 (fr) 2007-05-22 2008-11-26 Novartis AG Compositions de triazole pour traiter la formation de biofilm
KR101787112B1 (ko) 2008-06-09 2017-11-15 루드비히-막시밀리안스-우니버지테트 뮌헨 신경변성 질환 및/또는 단백질 응집과 연관된 질환과 관련된 단백질의 응집을 억제하기 위한 신규 약물

Also Published As

Publication number Publication date
PE20110930A1 (es) 2012-01-20
RS53613B1 (sr) 2015-04-30
SI2328417T1 (sl) 2014-12-31
CO6382089A2 (es) 2012-02-15
CL2011000739A1 (es) 2011-09-23
CN102170787B (zh) 2014-11-12
ME02017B (me) 2015-05-20
PL2328417T3 (pl) 2015-02-27
EP2328417A1 (fr) 2011-06-08
HRP20140967T1 (hr) 2014-12-05
CA2735120C (fr) 2014-07-22
NZ591504A (en) 2012-11-30
US8592476B2 (en) 2013-11-26
WO2010039308A1 (fr) 2010-04-08
US20090111863A1 (en) 2009-04-30
MY156302A (en) 2016-01-29
MX2011002830A (es) 2011-06-24
EP2328417A4 (fr) 2012-06-27
RU2011117544A (ru) 2012-11-10
CY1115725T1 (el) 2017-01-25
BRPI0920687A2 (pt) 2015-08-18
AU2009300298A1 (en) 2010-04-08
PT2328417E (pt) 2014-10-16
ES2519140T3 (es) 2014-11-06
US8829198B2 (en) 2014-09-09
IL211313A (en) 2013-12-31
IL211313A0 (en) 2011-04-28
RU2501792C2 (ru) 2013-12-20
JP5431485B2 (ja) 2014-03-05
AU2016201693A1 (en) 2016-04-07
KR20110086549A (ko) 2011-07-28
UA101393C2 (ru) 2013-03-25
DK2328417T3 (da) 2014-11-03
JP2012504617A (ja) 2012-02-23
US20120252858A1 (en) 2012-10-04
ZA201101278B (en) 2012-02-29
CA2735120A1 (fr) 2010-04-08
CN102170787A (zh) 2011-08-31
EP2328417B1 (fr) 2014-08-13

Similar Documents

Publication Publication Date Title
MA32686B1 (fr) Composés, compositions et procédés pour le traitement de maladies de la b-amyloïde et de synucléinopathies
MA33295B1 (fr) Nouvelle formulation de diclofénac
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
MA37610B1 (fr) Formulations de testostérone proliposomales
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA38837B1 (fr) Inhibiteurs de l'autotaxine contenant un noyau à cycle benzyle-amide cyclique hétéroaromatique
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
MA37886B1 (fr) Nouvelles pyridinones bicycliques
EP2268647A4 (fr) Composés et compositions pour la détection et le traitement de la maladie d'alzheimer et des troubles associés
CL2008002308A1 (es) Compuestos heterociclos, moduladores de beta secretasa; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos utiles para reducir la produccion de beta amiloide; y kit que contiene a uno de los compuestos, utiles para tratar enfermedades neurodegenerativas, tal como alzheimer.
MA35576B1 (fr) Nouveaux composés
EP2352497A4 (fr) Compositions contenant des esters d'acides aminés delta-9-thc et leur procédé de préparation
EP2331095A4 (fr) Certains inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci
MA29169B1 (fr) Formulations intraveineuses d'inhibiteurs de la pde-5
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
MA30466B1 (fr) Nouvelle forme d'administration du racecadotril
MA35567B1 (fr) Nouvelle formulation de méloxicam
EP2142549A4 (fr) Dérivés d'adénosine, procédé pour la synthèse de ces derniers, et compositions pharmaceutiques pour la prévention et le traitement de maladies inflammatoires contenant lesdits dérivés en tant qu'ingrédients actifs
MX2011011459A (es) Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb
MA37763A1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1